Inhibrx Biosciences Inc (INBX)

$87.41 +4.45 (5.36%)
Market Cap 1.20B
Revenue (ttm) 200,000.00
Net Income (ttm) 1.69B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 843,784.96%
Debt to Equity Ratio 1.45
Volume 275,700
Avg Vol 425,526
Day's Range N/A - N/A
Shares Out 14.54M
Stochastic %K 49%
Beta 1.18
Analysts Hold
Price Target $12.00

Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma,...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 795 4220
Website: inhibrx.com
Address:
11025 North Torrey Pines Road, Suite 140, La Jolla, United States
Iightning
Iightning Dec. 4 at 11:01 PM
1ightning® Premium Options Alert (Actionable) Ticker: $INBX Contract: Dec 19 $90C Entry: 9.25 Exit: 14.85 Return: +60.54% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Okadarlan
Okadarlan Dec. 4 at 3:57 PM
$INBX opened a big short @IjustTradeiT
1 · Reply
Iightning
Iightning Dec. 4 at 6:41 AM
1ightning® Premium Options Alert (Actionable) Ticker: $INBX Contract: Dec 19 $85C Entry: 9.85 Exit: 13.13 Return: +33.25% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
QuantInsider
QuantInsider Dec. 4 at 2:47 AM
$INBX had a lone ask side Dec 19 $50 put block today 500 contracts at $0.90, which is 40% OTM Looks more like hedge demand than a big short bet since it's smaller than open interest No sweeps and no new catalysts in the last 48 hours Price is up 0.86% today but down 1.95% over 5 days Flow and price aren't aligning yet I'd wait for more ask side put sweeps or an IV lift before considering a short play For now it’s just protection or positioning Keep an eye out for more signals or a 5-day breakdown before making a move
0 · Reply
Iightning
Iightning Dec. 3 at 10:14 AM
1ightning® Premium Options Alert (Actionable) Ticker: $INBX Contract: Dec 19 $65C Entry: 20.00 Exit: 35.34 Return: +76.69% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 2 at 1:00 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $INBX **Contract:** Dec 19 $85C **Entry:** 8.57 **Exit:** 13.49 **Return:** **+57.36% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
MichaelKTrades
MichaelKTrades Nov. 26 at 9:44 PM
$INBX Another tight big base
0 · Reply
Isthistherightdirection
Isthistherightdirection Nov. 26 at 12:17 PM
$INBX I bet this gets bought out by Sanofi $SNY
0 · Reply
Iightning
Iightning Nov. 26 at 3:54 AM
1ightning® Options Trade Alert (Actionable) | Buy $INBX Dec 19 $85 Call | Enter: $9.18 Exit: $16.20 | Profit: 76.53% ROI | https://1ightning.com
0 · Reply
Isthistherightdirection
Isthistherightdirection Nov. 25 at 7:58 PM
$INBX Nice green candle.
0 · Reply
Latest News on INBX
Inhibrx Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 6:00 AM EST - 20 days ago

Inhibrx Reports Third Quarter 2025 Financial Results

Inhibrx Announces Participation in Upcoming Scientific Conferences

Nov 4, 2025, 4:01 PM EST - 4 weeks ago

Inhibrx Announces Participation in Upcoming Scientific Conferences

Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing

Oct 24, 2025, 3:31 PM EDT - 5 weeks ago

Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing

Inhibrx shares surge after bone cancer drug slows disease progression in trial

Oct 23, 2025, 6:39 PM EDT - 6 weeks ago

Inhibrx shares surge after bone cancer drug slows disease progression in trial

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Oct 23, 2025, 4:05 PM EDT - 6 weeks ago

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Oct 22, 2025, 4:01 PM EDT - 6 weeks ago

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Inhibrx Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 4:05 PM EDT - 4 months ago

Inhibrx Reports Second Quarter 2025 Financial Results

Inhibrx Reports First Quarter 2025 Financial Results

May 14, 2025, 4:05 PM EDT - 7 months ago

Inhibrx Reports First Quarter 2025 Financial Results

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Apr 1, 2025, 4:05 PM EDT - 8 months ago

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 17, 2025, 4:05 PM EDT - 9 months ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Jan 21, 2025, 5:01 PM EST - 11 months ago

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Jan 13, 2025, 4:15 PM EST - 11 months ago

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:24 PM EST - 1 year ago

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Nov 5, 2024, 11:45 AM EST - 1 year ago

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Nov 4, 2024, 4:00 PM EST - 1 year ago

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying

Aug 27, 2024, 7:10 AM EDT - 1 year ago

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying

HNRG TCBI

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 13, 2024, 6:54 PM EDT - 1 year ago

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Jun 7, 2024, 2:42 PM EDT - 1 year ago

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

Jun 5, 2024, 7:46 AM EDT - 1 year ago

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

A EXAS TDOC

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

May 24, 2024, 4:00 PM EDT - 1 year ago

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

May 10, 2024, 6:36 PM EDT - 1 year ago

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

May 9, 2024, 3:36 PM EDT - 1 year ago

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SNY

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

May 8, 2024, 4:37 PM EDT - 1 year ago

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 28, 2024, 9:15 AM EST - 1 year ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

Jan 23, 2024, 11:45 AM EST - 2 years ago

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

SNY

Sanofi to Buy Rare-Disease Assets From Inhibrx

Jan 23, 2024, 5:39 AM EST - 2 years ago

Sanofi to Buy Rare-Disease Assets From Inhibrx

SNY

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

Jan 23, 2024, 1:32 AM EST - 2 years ago

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

SNY

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

Jan 23, 2024, 1:30 AM EST - 2 years ago

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

SNY

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

Jan 23, 2024, 1:00 AM EST - 2 years ago

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

SNY

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 9, 2023, 4:00 PM EST - 2 years ago

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Sep 19, 2023, 4:00 PM EDT - 2 years ago

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Andreas Halvorsen's Firm Ups Inhibrx Stake

Sep 1, 2023, 4:26 PM EDT - 2 years ago

Andreas Halvorsen's Firm Ups Inhibrx Stake

Inhibrx Announces $200 Million Private Placement Financing

Aug 29, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Announces $200 Million Private Placement Financing

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

Aug 17, 2023, 4:41 PM EDT - 2 years ago

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 7, 2023, 4:00 PM EDT - 2 years ago

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 30, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 8, 2023, 4:05 PM EDT - 2 years ago

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Apr 26, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Inhibrx: Undercovered Company With Good Potential

Apr 13, 2023, 11:12 AM EDT - 2 years ago

Inhibrx: Undercovered Company With Good Potential

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Mar 6, 2023, 4:05 PM EST - 2 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

Jan 4, 2023, 9:00 AM EST - 3 years ago

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

Inhibrx Announces Participation in Upcoming Investor Conference

Nov 18, 2022, 4:05 PM EST - 3 years ago

Inhibrx Announces Participation in Upcoming Investor Conference

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

Nov 16, 2022, 9:00 AM EST - 3 years ago

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 7, 2022, 4:05 PM EST - 3 years ago

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Oct 4, 2022, 8:00 AM EDT - 3 years ago

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

Oct 3, 2022, 4:30 PM EDT - 3 years ago

Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

Aug 15, 2022, 4:05 PM EDT - 3 years ago

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

Iightning
Iightning Dec. 4 at 11:01 PM
1ightning® Premium Options Alert (Actionable) Ticker: $INBX Contract: Dec 19 $90C Entry: 9.25 Exit: 14.85 Return: +60.54% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Okadarlan
Okadarlan Dec. 4 at 3:57 PM
$INBX opened a big short @IjustTradeiT
1 · Reply
Iightning
Iightning Dec. 4 at 6:41 AM
1ightning® Premium Options Alert (Actionable) Ticker: $INBX Contract: Dec 19 $85C Entry: 9.85 Exit: 13.13 Return: +33.25% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
QuantInsider
QuantInsider Dec. 4 at 2:47 AM
$INBX had a lone ask side Dec 19 $50 put block today 500 contracts at $0.90, which is 40% OTM Looks more like hedge demand than a big short bet since it's smaller than open interest No sweeps and no new catalysts in the last 48 hours Price is up 0.86% today but down 1.95% over 5 days Flow and price aren't aligning yet I'd wait for more ask side put sweeps or an IV lift before considering a short play For now it’s just protection or positioning Keep an eye out for more signals or a 5-day breakdown before making a move
0 · Reply
Iightning
Iightning Dec. 3 at 10:14 AM
1ightning® Premium Options Alert (Actionable) Ticker: $INBX Contract: Dec 19 $65C Entry: 20.00 Exit: 35.34 Return: +76.69% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 2 at 1:00 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $INBX **Contract:** Dec 19 $85C **Entry:** 8.57 **Exit:** 13.49 **Return:** **+57.36% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
MichaelKTrades
MichaelKTrades Nov. 26 at 9:44 PM
$INBX Another tight big base
0 · Reply
Isthistherightdirection
Isthistherightdirection Nov. 26 at 12:17 PM
$INBX I bet this gets bought out by Sanofi $SNY
0 · Reply
Iightning
Iightning Nov. 26 at 3:54 AM
1ightning® Options Trade Alert (Actionable) | Buy $INBX Dec 19 $85 Call | Enter: $9.18 Exit: $16.20 | Profit: 76.53% ROI | https://1ightning.com
0 · Reply
Isthistherightdirection
Isthistherightdirection Nov. 25 at 7:58 PM
$INBX Nice green candle.
0 · Reply
Isthistherightdirection
Isthistherightdirection Nov. 25 at 5:20 PM
$INBX $85?
0 · Reply
Iightning
Iightning Nov. 25 at 1:59 PM
1ightning® Options Trade Alert (Actionable) | Buy $INBX Dec 19 $85 Call | Enter: $9.18 Exit: $16.20 | Profit: 76.53% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 2:52 AM
1ightning® Options Trade Alert (Actionable) | Buy $INBX Dec 19 $85 Call | Enter: $9.18 Exit: $16.20 | Profit: 76.53% ROI | https://1ightning.com
0 · Reply
aletz
aletz Nov. 24 at 10:06 PM
$INBX https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk4/ On Top 10 list from this week's scan result
1 · Reply
Number99
Number99 Nov. 22 at 1:44 AM
$INBX 1- Most of pharma and big biotech are facing significant loss of exclusivity cliffs over the next five-plus years; 2- ozekibart is EXTREMELY likely to get FDA approval; 3- in addition to single-agent activity, ozekibart has great combo potential in big oncology disease markets (e.g. colorectal), and with IO drugs that almost every pharma has in their toolkit and need to extend IO lifespan. The question is not if ozekibart will be transacted, the question is when and for how much.
1 · Reply
Iightning
Iightning Nov. 22 at 12:07 AM
1ightning® Options Trade Alert (Actionable) | Buy $INBX Dec 19 $80 Call | Enter: $10.25 Exit: $16.34 | Profit: 59.40% ROI | https://1ightning.com
0 · Reply
Alicoya
Alicoya Nov. 21 at 9:16 PM
$INBX nobody would pay over 1b usd to a company which is working for a drug where no other big pharma succeeded yet. they should first present their bla which is forecasted for Q2 2026. if the approval fails ; see you at 10 usd
1 · Reply
Braindead83
Braindead83 Nov. 21 at 5:31 PM
$INBX for all the bulls out there. Let’s say that INBX does not get acquired, where do you think this trades without the current acquisition premium priced in?
1 · Reply
Iightning
Iightning Nov. 21 at 3:27 AM
1ightning® Options Trade Alert (Actionable) | Buy $INBX Dec 19 $80 Call | Enter: $10.25 Exit: $16.34 | Profit: 59.40% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 20 at 12:52 AM
1ightning® Options Trade Alert (Actionable) | Buy $INBX Dec 19 $80 Call | Enter: $10.25 Exit: $16.34 | Profit: 59.40% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 9:04 AM
1ightning® Options Trade Alert (Actionable) | Buy $INBX Dec 19 $80 Call | Enter: $10.25 Exit: $16.34 | Profit: 59.40% ROI | https://1ightning.com
0 · Reply
judgeyoung2
judgeyoung2 Nov. 17 at 9:03 PM
$XBI dough on X is a fraud. fear mongered on $TERN at $7. now it’s $25. fear mongered on $INBX at $45. now $77. he just shills Viking. i like Viking, but he has tunnel vision.
0 · Reply